Bavarian Nordic Announces Interim Results for the First Three Months of 2019

NEXT STORY
Centauri’s AlphamerTM Platform highlighted at 4th Annual Advances in Immuno-Oncology Congress
PREV STORY
Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY SYNDROME

INNATE PHARMA RECEIVES FDA FAST TRACK DESIGNATION FOR IPH4102 IN RELAPSED OR REFRACTORY SÉZARY ...

author_avatar
NASDAQ Market News

United Health Products Forms Medical Advisory Board

HENDERSON, Nev., March 19, 2018 (GLOBE NEWSWIRE) -- United Health Products, Inc. (UHP) (OTC:UEEC), ...

author_avatar
NASDAQ Market News

Basilea reports presentation of phase 1 clinical data with anticancer drug candidate BAL101553 at ASCO meeting

Data support expansion into phase 2a Basel, Switzerland, June 05, 2018 - Basilea Pharmaceutica ...

author_avatar
NASDAQ Market News